Bacterial drug resistance is a global problem and challenge in anti-infective treatment, and multi-drug-resistant bacterial infections are facing the situation of having no choice of drugs in the clinic. (hereinafter referred to as "Consensus") was authoritatively released, aiming to provide clinicians with an authoritative treatment guideline to help them choose treatment options more scientifically and rationally when facing multidrug-resistant bacterial infections.

Multi-drug resistant bacteria (MDRB) refers to bacteria that are resistant to three or more classes of commonly used antibacterial drugs that are usually sensitive. In the treatment of MDRB infections, polymyxins, such as polymyxin B and polymyxin E (CMS), have become a powerful weapon against drug-resistant bacteria due to their unique antimicrobial mechanisms and remarkable efficacy. These drugs exert their antimicrobial effects by binding to lipopolysaccharide on the bacterial cell membrane and disrupting the integrity of the cell membrane.

Polymyxin E sodium methanesulfonate has been widely used in the clinical treatment of a variety of drug-resistant bacterial infections at home and abroad, and has been preferentially recommended for nebulized inhalation for lung infections and ventricular/intrathecal injection for central nervous system infections [1, 2]. This Consensus further standardizes the clinical use of nebulized inhalation therapy with sodium polymyxin E methanesulfonate, e.g., for nebulized inhalation therapy with sodium polymyxin E methanesulfonate, the recommended dosage for adults and children older than 2 years of age is a single dose of 2 million units (approximately 66 mg of CBA), 2-3 times per day.

In addition, two Chinese real-world retrospective studies of Chiatai Tianqing Polymyxin E Sodium Methanesulfonate (Trademark Name: Tianyun) were selected for poster presentation at the conference.

In the field of anti-infective, Chiatai Tianqing has deeply laid out anti-negative bacteria, anti-positive bacteria, anti-drug-resistant bacteria and anti-fungal and other directions, and the listed products, such as Tianyun (Sodium Polymyxin E Methanesulfonate), Tianzhu (Biaxepinam), Tianxie (Tigecycline), Tianli (Linezolid), Tianming (Carbophenazimin), etc., have formed the anti-infective therapeutic matrix, and there are also heavy-weight products such as Dolipenem, Posaconazole, and Carbopenem in the pipeline. The anti-infective products under research and development also include Doripenem, Posaconazole and Carbapenem compound preparation and other important products. In the future, Chiatai Tianqing will continue to launch high-quality products oriented to the unmet clinical needs to protect the health of the people in China.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650367831&idx=1&sn=5f57da0e211ec326d68d021529d46a73&chksm=885fa2e0bf282bf6b8c04a7078caebd15f80a89b8d8f2ffacd6544abd018d3bfa2415eb0fcfb&mpshare=1&scene=1&srcid=07103mdjWe0nZDXUh13LdYAi&sharer_shareinfo=7e8ff0c556d36fcd2d6355f40a06a748&sharer_shareinfo_first=7e8ff0c556d36fcd2d6355f40a06a748#rd